Home > Cardiology > AHA 2020 > Miscellaneous > PAD: Rivaroxaban reduces VTE risk after revascularisation

PAD: Rivaroxaban reduces VTE risk after revascularisation

Presented By
Dr Connie Hess; Prof. Judith Hsia
Conference
AHA 2020
Trial
VOYAGER PAD

Peripheral artery disease (PAD) is associated with a linearly increased risk of venous thromboembolism (VTE) after lower extremity revascularisation. A secondary analysis of the VOYAGER PAD study showed that adding low-dose rivaroxaban to aspirin reduced VTE risk by 39% [1]. In another analysis of VOYAGER PAD, rivaroxaban reduced the composite endpoint of major cardiovascular (CV) and limb events in PAD patients with chronic kidney disease (CKD) [2].

In the VOYAGER PAD study (NCT02504216), patients with lower extremity PAD undergoing revascularisation were randomised to rivaroxaban 2.5 mg twice daily plus aspirin (n=3,286) or placebo plus aspirin (n=3,278) [3]. The primary efficacy outcome of CV death, acute limb ischaemia, major amputation, myocardial infarction, or stroke occurred in 17.3% and 19.9%, respectively (HR 0.85; 95% CI 0.76–0.96; P=0.0...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on